Imaginostics

About Imaginostics

Imaginostics develops non-invasive quantitative imaging technology compatible with existing MRI scanners to assess vascular health and disease. Their solutions provide early diagnostics and drug efficacy evaluation, enhancing patient care through detailed visualization of structural and functional abnormalities.

```xml <problem> Current methods for assessing vascular health often involve invasive procedures or lack the sensitivity to detect subtle structural and functional abnormalities in early stages of disease. This can lead to delayed diagnoses and limit the ability to evaluate the effectiveness of new therapies. </problem> <solution> Imaginostics develops non-invasive quantitative imaging technology that integrates with existing MRI scanners to provide detailed assessments of vascular health and disease. Their technology uses advanced quantitative imaging biomarkers to visualize the vasculature and identify structural and functional abnormalities. The resulting data can be used for early diagnostics, patient stratification, and drug efficacy evaluation in clinical trials. By providing a comprehensive view of vascular health, Imaginostics aims to improve patient care through earlier detection and more informed treatment decisions. </solution> <features> - Non-invasive quantitative imaging biomarkers for assessing vascular structure and function - Compatible with existing MRI scanners and hardware - Full-body health assessment of vascular abnormalities - Biomarker solutions for neurologic disease, neurofunctional pharmacokinetics, cardiac, kidney, and cancer applications - Visualization of the vasculature to assay health and disease - Tools to stratify patient populations </features> <target_audience> The primary audience includes clinicians, researchers, and pharmaceutical companies focused on neuroscience, cancer, and cardiology, particularly those interested in early diagnostics, precision medicine, and drug development. </target_audience> ```

What does Imaginostics do?

Imaginostics develops non-invasive quantitative imaging technology compatible with existing MRI scanners to assess vascular health and disease. Their solutions provide early diagnostics and drug efficacy evaluation, enhancing patient care through detailed visualization of structural and functional abnormalities.

Where is Imaginostics located?

Imaginostics is based in Orlando, United States.

When was Imaginostics founded?

Imaginostics was founded in 2018.

How much funding has Imaginostics raised?

Imaginostics has raised 5300000.

Location
Orlando, United States
Founded
2018
Funding
5300000
Employees
8 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

Imaginostics

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

Imaginostics develops non-invasive quantitative imaging technology compatible with existing MRI scanners to assess vascular health and disease. Their solutions provide early diagnostics and drug efficacy evaluation, enhancing patient care through detailed visualization of structural and functional abnormalities.

imaginostics.com500+
cb
Crunchbase
Founded 2018Orlando, United States

Funding

$

Estimated Funding

$5M+

Team (5+)

No team information available.

Company Description

Problem

Current methods for assessing vascular health often involve invasive procedures or lack the sensitivity to detect subtle structural and functional abnormalities in early stages of disease. This can lead to delayed diagnoses and limit the ability to evaluate the effectiveness of new therapies.

Solution

Imaginostics develops non-invasive quantitative imaging technology that integrates with existing MRI scanners to provide detailed assessments of vascular health and disease. Their technology uses advanced quantitative imaging biomarkers to visualize the vasculature and identify structural and functional abnormalities. The resulting data can be used for early diagnostics, patient stratification, and drug efficacy evaluation in clinical trials. By providing a comprehensive view of vascular health, Imaginostics aims to improve patient care through earlier detection and more informed treatment decisions.

Features

Non-invasive quantitative imaging biomarkers for assessing vascular structure and function

Compatible with existing MRI scanners and hardware

Full-body health assessment of vascular abnormalities

Biomarker solutions for neurologic disease, neurofunctional pharmacokinetics, cardiac, kidney, and cancer applications

Visualization of the vasculature to assay health and disease

Tools to stratify patient populations

Target Audience

The primary audience includes clinicians, researchers, and pharmaceutical companies focused on neuroscience, cancer, and cardiology, particularly those interested in early diagnostics, precision medicine, and drug development.

Want to add first party data to your startup here or get your entry removed? You can edit it yourself by logging in with your company domain.